Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

On January 3, 2022 Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, reported that David Marek, Chief Executive Officer of Myovant Sciences, Inc., will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 p.m. Eastern Time (Press release, Myovant Sciences, JAN 3, 2022, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-present-40th-annual-jp-morgan-healthcare [SID1234597957]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to the presentation, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!